About Hookipa Pharma
Hookipa Pharma (NASDAQ:HOOK) is a biotechnology company focused on developing a new class of immunotherapeutics based on its proprietary arenavirus platform technologies. The company is dedicated to creating innovative treatments for infectious diseases and cancers, harnessing the power of the immune system to combat these serious conditions. Through its cutting-edge research and development, Hookipa is advancing a diverse pipeline of potential therapies, including novel vaccines and immune-oncology products. The company's objectives revolve around transforming the therapeutic landscape by delivering highly effective, durable, and safe options for patients in need across the globe. With a relentless pursuit of groundbreaking solutions, Hookipa is committed to making a meaningful difference in the lives of those affected by challenging diseases.
Snapshot
Operations
Products and/or services of Hookipa Pharma
- HB-101, a prophylactic cytomegalovirus vaccine, aiming to prevent congenital CMV infection.
- HB-200 series, using an arenavirus platform for HPV16+ cancers, including head, neck, and cervical cancers.
- HB-300, a therapeutic vaccine targeting human papillomavirus-positive cancers.
- Oncology viral vector platforms, focusing on arenavirus-based vectors for solid tumors.
- Immuno-oncology programs, developing novel arenavirus-based therapeutics to reprogram the immune system against cancer.
- Research collaborations, partnering with biotech and pharma for vaccine and immuno-oncology development.
Hookipa Pharma executive team
- Dr. Malte Peters M.D.CEO, President & Director
- Ms. Mary Theresa Coelho M.B.A.Executive VP, CFO & Director
- Dr. Daniel D. Pinschewer M.D.Co-Founder & Member of Scientific Advisory Board
- Dr. Mark Winderlich Ph.D.Chief Research & Development Officer